Results 91 to 100 of about 7,679 (193)

Mepolizumab treatment in patients with severe eosinophilic asthma. [PDF]

, 2014
BACKGROUND: Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids.
Pavord, Ian D., Oliver N. Keene, Yancey, Steven W., Brusselle, Guy G., Liu, MC, Chanez, P, Liu, Mark C, Brusselle, GG, Humbert, M, FitzGerald, J. Mark, Hector G. Ortega, FitzGerald, J Mark, Ian D. Pavord, Pavord, ID, Marc Humbert, Katz, LE, Chanez, Pascal, Steven W. Yancey, Katz, Lynn E, J. Mark FitzGerald, Yancey, Steven W, Mark C. Liu, Guy G. Brusselle, Chetta, Alfredo, Humbert, Marc, Keene, ON, Lynn E. Katz, FitzGerald, JM, Ortega, Hector G., Keene, Oliver N., Keene, Oliver N, Ortega, HG, Pascal Chanez, CANONICA, GIORGIO, CHETTA, Alfredo Antonio, Ortega, Hector G, Liu, Mark C., Brusselle, Guy, Chetta, A, Brusselle, Guy G, Pavord, Ian D, Katz, Lynn E., Yancey, SW   +42 more
core   +1 more source

Longer Asthma Duration Is Associated With Elevated Non‐T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma

Allergy, EarlyView.
Longer asthma duration is associated with increased airway non‐T2 inflammation and reduced airway and systemic T2 inflammation. Sputum CXCL9 is independently associated with duration and may predict a reduced poor response to anti‐IL‐4Rα therapy. Airway sampling and combined T2 and non‐T2 targeted strategies may be needed in long‐standing asthma. CXCL9,
Freda Yang, Sujin Seo, Takehiro Hasegawa, Chloe I. Bloom, Nazanin Zounemat‐Kermani, Pankaj K. Bhavsar, Katie Raby, Ian M. Adcock, Sungho Won, Tae‐Bum Kim, Kian Fan Chung, on behalf of the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) Consortium, M. I. Abdel‐Aziz, C. Auffray, Y. E. Badi, P. Bakke, A. T. Bansal, F. Baribaud, S. Bates, A. F. Behndig, E. H. Bel, J. Bigler, B. Billing, M. J. Boedigheimer, K. Bønnelykke, J. Brandsma, P. Brinkman, E. Bucchioni, D. Burg, A. Bush, M. Caruso, R. Chalekis, P. Chanez, B. Chaves, F. K. Chung, T. Checa, C. H. Compton, J. Corfield, D. Cunoosamy, A. D'Amico, B. Dahlén, B. De Meulder, R. Djukanovic, V. J. Erpenbeck, D. Erzen, K. Fichtner, L. J. Fleming, E. Formaggio, S. J. Fowler, U. Frey, M. Gahlemann, T. Geiser, V. Goss, Y. Guo, S. Hashimoto, J. Haughney, G. Hedlin, P. W. Hekking, T. Higenbottam, J. M. Hohlfeld, C. Holweg, I. Horváth, P. Howarth, A. J. James, R. G. Knowles, J. Kolmert, J. Konradsen, N. Krug, N. Lazarinis, C.‐X. Li, M. J. Loza, R. Lutter, A. Manta, S. Masefield, Maitland‐van der Zee Anke‐Hilse, J. G. Matthews, A. Mazein, R. J. M. Middelveld, M. Miralpeix, C. S. Murray, J. Musial, S. Mumby, D. Myles, B. Nordlund, H. Olsson, I. Pandis, S. Pavlidis, A. Platt, A. Postle, P. Powel, G. Praticò, M. Puig Valls, N. Rao, S. Reinke, J. Riley, A. Roberts, G. Roberts, A. Rowe, T. Sandström, J. P. R. Schofield, W. Seibold, D. E. Shaw, R. Sigmund, F. Singer, P. J. Skipp, M. Smicker, A. R. Sousa, M. Sparreman‐Mikus, P. J. Sterk, K. Sun, B. Thornton, A. Versi, N. H. Vissing, A. M. Wheelock, C. E. Wheelock, S. J. Wilson, V. Yasinska, Aliprantis Antonios, Allen David, Alving Kjell, P. Badorrek, Balgoma David, S. Ballereau, Barber Clair, Batuwitage Manohara Kanangana, Bautmans An, A. Bedding, A. F. Behndig, Beleta Jorge, A. Berglind, Bochenek Grazyna, Braun Armin, D. Campagna, Carayannopoulos Leon, C. Casaulta, A. Chaiboonchoe, Chaleckis Romanas, Davison Timothy, De Alba Jorge, Dekker Tamara, Delin Ingrid, P. Dennison, Dijkhuis Annemiek, Dodson Paul, Draper Aleksandra, K. Dyson, Edwards Jessica, L. El Hadjam, Emma Rosalia, C. Faulenbach, Flood Breda, G. Galffy, Gallart Hector, D. Garissi, J. Gent, M. Gerhardsson de Verdier, D. Gibeon, Gomez Cristina, Gove Kerry, Gozzard Neil, E. Guillmant‐Farry, E. Henriksson, Hewitt Lorraine, U. Hoda, Hu Richard, Hu Sile, X. Hu, E. Jeyasingham, K. Johnson, N. Jullian, Kamphuis Juliette, J. Kennington Erika, Kerry Dyson, G. Kerry, M. Klüglich, Knobel Hugo, J. Knox Alan, Kolmert Johan, J. R. Konradsen, Kots Maxim, Kretsos Kosmas, L. Krueger, Kuo Scott, Kupczyk Maciej, A.‐S Lantz, Larminie Christopher, L. X. Larsson, P. Latzin, N. Lazarinis, Lefaudeux Diane, N. Lemonnier, Li Chuan‐Xing, Lone‐Latif Saeeda, L. A. Lowe, Manta Alexander, Marouzet Lisa, Martin Jane, Mathon Caroline, L. McEvoy, Meah Sally, A. Menzies‐Gow, Metcalf Leanne, Meiser Andrea, Mikus Maria, Monk Philip, N. Mores, Naz Shama, K. Nething, Nicholas Ben, U. Nihlén, Nilsson Peter, R. Niven, B. Nordlund, S. Nsubuga, Pacino Antonio, Palkonen Susanna, L. Pahus, J. Pellet, Pennazza Giorgio, Petrén Anne, Pink Sandy, C. Pison, Rahman‐Amin Malayka, Ravanetti Lara, Ray Emma, Reinke Stacey, Reynolds Leanne, K. Riemann, Robberechts Martine, J. P. Rocha, C. Rossios, Russell Kirsty, Rutgers Michael, G. Santini, Santonico Marco, M. Saqi, Schoelch Corinna, S. Scott, N. Sehgal, A. Selby, Sjödin Marcus, Smids Barbara, Smith Caroline, Smith Jessica, M. Smith Katherine, P. Söderman, A. Sogbesan, F. Spycher, Staykova Doroteya, S. Stephan, J. Stokholm, K. Strandberg, M. Sunther, M. Szentkereszty, L. Tamasi, K. Tariq, Thörngren John‐Olof, Thorsen Jonathan, S. Valente, W. M. van Aalderen, Marianne van de Pol, C. M. van Drunen, Van Eyll Jonathan, Versnel Jenny, Vink Anton, C. von Garnier, A. Vyas, A. H. Wagener, Wald Frans, Walker Samantha, Ward Jonathan, Wetzel Kristiane, Wiegman Coen, Z. Weiszhart, Williams Siân, Yang Xian, Yeyasingham Elizabeth, W. Yu, W. Zetterquist, Z. Zolkipli, A. H. Zwinderman, Lega Italiano Anti Fumo, A. B. Aerocrine, N. V. Amgen, Merck Sharp, Martina Gahlemann, Luigi Visintin, Hazel Evans, Martine Puhl, Lina Buzermaniene, Val Hudson, Laura Bond, Pim de Boer, Guy Widdershoven, Ralf Sigmund, David Supple, Dominique Hamerlijnck, Jenny Negus, Juliёtte Kamphuis   +298 more
wiley   +1 more source

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study

Journal of Asthma and Allergy, 2019
Jean-Pierre Llanos,1 Christopher F Bell,1 Elizabeth Packnett,2 Ellen Thiel,2 Debra E Irwin,2 Beth Hahn,1 Hector Ortega3 1Respiratory, US Medical Affairs, GSK, Research Triangle Park, NC, USA; 2Truven Health Analytics, An IBM Watson Health Company, Ann ...
Llanos JP, Bell CF, Packnett E, Thiel E, Irwin DE, Hahn B, Ortega H   +6 more
doaj  

Retention of a Patency Capsule Shell in a Nonsteroidal Anti‐Inflammatory Drug‐Induced Small‐Bowel Stricture, Detected and Retrieved by Balloon‐Assisted Enteroscopy: Emphasizing the Importance of Confirming Capsule Excretion

Journal of Digestive Diseases, EarlyView.
Shinichiro Kawatoko, Tomohiro Nagasue, Akihiro Shigemori, Akihiro Yoshida, Junji Umeno   +4 more
wiley   +1 more source

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Depemokimab is the first ultra‐long‐acting biologic with enhanced interleukin‐5 (IL‐5) binding affinity, high potency, and extended half‐life, enabling twice‐yearly dosing. Depemokimab has demonstrated efficacy and safety in patients with asthma and chronic rhinosinusitis with nasal polyps.
Anders Thorsted, Lénaïg Tanneau, Alexandra Lavalley‐Morelle, Richard Follows, Loretta Jacques, Nicholas Bird, Philippe Gevaert, Ian Pavord, Jakob Ribbing, Anubha Gupta, Peter Howarth, Stein Schalkwijk   +11 more
wiley   +1 more source

Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level

Scientific Reports
To date, most studies to identify biomarkers associated with response to the anti-interleukin 5 agent, mepolizumab, and to the anti-immunoglobulin E agent, omalizumab have focused on clinically available biomarkers, such as the peripheral blood ...
Ayobami Akenroye, Tanawin Nopsopon, Jonathan J. Hacker, Tanya M. Laidlaw   +3 more
doaj   +1 more source

Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

ClinicoEconomics and Outcomes Research, 2022
Bassam Mahboub,1 Ahmed Mohy,2 Islam El-Amir,2 Tamara Lukić,3 Raef Gouhar,4 Saeed Noibi5 1Pulmonary Medicine Department, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates; 2Medical Affairs Department, GSK, Jeddah, Kingdom of ...
Mahboub B, Mohy A, El-Amir I, Lukić T, Gouhar R, Noibi S   +5 more
doaj  

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Mepolizumab: um novo tratamento para a asma [PDF]

, 2017
Introdução:   O Mepolizumab é um anticorpo monoclonal anti IL-5 coadjuvante no tratamento da asma e eficaz no controle dos sintomas e na redução da mortalidade.
Dias, Elisa, Fortuce, Flávia, Beatriz Assunção, Ferreira, Camilla, Camilla Santos, Braga, Marthina, José Barbosa Junior, Flávia Fortuce, Camilla Ferreira, Marthina Braga, Santos, Camilla, Elisa Dias, Assunção, Beatriz, Junior, José Barbosa   +13 more
core   +1 more source